SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Meta Expands AI Training With Employee Activity Tracking Tools 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
NEW YORK, March 13, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Kitov Pharmaceutical Holdings Ltd. securities (NASDAQ:KTOV) pursuant and/or traceable to Kitov’s initial public offering on or about November 20, 2015 (the “IPO”) and/or on the open market from November 20, 2015 through February 3, 2017, both dates inclusive (the “Class Period”) of the important April 10, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Kitov investors under the federal securities laws.
To join the Kitov class action, go to http://www.rosenlegal.com/cases-1051.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Kitov and its CEO Isaac Israel published misleading information concerning the conduct of Kitov’s clinical trials for its lead drug candidate KIT-302; and (2) as a result, Kitov’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 10, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1051.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
